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ABSTRACT 
Background: Dopamine D3 receptors are involved in the pathophysiology of several 
neuropsychiatric conditions.  [11C]-(+)-PHNO is a radiolabelled D2 and D3 agonist, suitable for 
imaging the agonist binding sites (denoted D2HIGH and D3) of these receptors with Positron 
Emission Tomography (PET).  PET studies in nonhuman primates documented that, in vivo, 
[11C]-(+)-PHNO displays a relative selectivity for D3 compared to D2HIGH receptor sites, and 
that the [11C]-(+)-PHNO signal is enriched in D3 contribution compared to conventional ligands 
such as [11C]raclopride. 
Methods: To define the D3 contribution (
3D
PHNOf ) to [11C]-(+)-PHNO binding potential 
(BPND) in healthy humans, fifty-two scans were obtained in nineteen healthy volunteers, at 
baseline and following oral administration of various doses of the selective D3 receptor 
antagonist, GSK598809. 
Results: The impact of GSK598809 on [11C]-(+)-PHNO was regionally selective.  In 
dorsal regions of the striatum, GSK598809 did not significantly affect [11C]-(+)-PHNO BPND 
( 3DPHNOf   0%).  Conversely, in the substantia nigra (SN), GSK598809 dose-dependently reduced 
[11C]-(+)-PHNO binding to nonspecific level  ( 3DPHNOf    100%).  In ventral striatum (VST), 
globus pallidus (GP) and thalamus (THA), [11C]-(+)-PHNO BPND was attributable to a 
combination of D2HIGH and D3 receptor sites, with 
3D
PHNOf  of 26%, 67% and 46%, respectively.  
D3 receptor binding potential (
3D
NDBP ) was highest in GP (1.90) and SN (1.39), with lower levels 
in VST (0.77) and THA (0.18) and negligible levels in dorsal striatum. 
Conclusions: This study elucidated the pharmacological nature of the [11C]-(+)-PHNO 
signal in healthy subjects, and provided the first quantification of D3 receptor availability with 
PET in the living human brain. 
 
Clinical trial details: “Study of Safety, Blood Levels and Brain Receptor Occupancy of 
GSK598809 Using PET Imaging in Health Males.”; clinicaltrial.gov identifier: NCT00468806. 
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INTRODUCTION 
Dopamine (DA) D3 receptors are members of the DA D2-like receptor family and are 
involved in functions mediated by the mesolimbic dopaminergic system, including reward and 
reinforcement.  A substantial body of literature supports the role of D3 receptors in the 
pathophysiology of several conditions such as addiction, schizophrenia and Parkinson’s disease 
(PD) and a number of D3 receptor agents are currently under development (1-4). 
Advances in the understanding of the role of D3 receptors in neuropsychiatric conditions 
have been limited by the lack of a method to measure D3 receptors in the living human brain.  
Radiotracers commonly used to image D2-like receptors with Positron Emission Tomography 
(PET), such as [11C]raclopride, [18F]fallypride or [11C]FLB457 are antagonists that display 
similar affinity for D2 and D3 receptors (5-7).  These receptors co-localize in brain regions where 
the density of D3 receptors is generally lower than that of D2 receptors.  Therefore, the D3 
receptor contribution to the signal of these conventional radiotracers tends to be quite small.  
Efforts to develop selective D3 receptor PET radiotracers have so far been unsuccessful.   
The demonstration of the in vivo D3 receptor preferring properties of the recently 
developed D2-like agonist PET radiotracer [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-
naphtho[1,2-b][1,4]oxazin-9-ol ([11C]-(+)-PHNO) opened up the possibility to image D3 
receptors with PET (8).  (+)-PHNO was first reported as a potent D2 agonist intended for the 
treatment of PD (9).  Initial evaluation of [11C]-(+)-PHNO in vivo binding in rats showed that 
[11C]-(+)-PHNO was a suitable agonist radiotracer to measure D2-like agonist receptor sites in 
the striatum (10).  Examination of [11C]-(+)-PHNO in vivo binding in humans demonstrated the 
expected high specific signal in the striatum, but revealed an unexpectedly high accumulation in 
the ventral striatum and globus pallidus compared to [11C]raclopride (11).  PET studies in 
baboons demonstrated that the enriched [11C]-(+)-PHNO signal in these regions was selectively 
decreased by pretreatment with the D3 receptor partial agonist BP-897, suggesting that the 
difference in regional distributions between [11C]raclopride and [11C]-(+)-PHNO was driven by 
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a relatively higher affinity of this tracer for D3 compared to D2HIGH receptor sites (8).  This 
finding was consistent with data from most but not all in vitro affinity studies (see Table 1 in 8).  
This proposition was recently confirmed by examining the effect of pretreatment with the 
selective D3 antagonist SB-277011 (100-fold selectivity for D3 over D2 in vitro) on in vivo 
[11C]-(+)-PHNO binding in baboons (12). 
 While the [11C]-(+)-PHNO in vivo signal is enriched in D3 versus D2 receptor 
contributions, selective pharmacological blockade is required to differentiate these components.  
Here, we report the in vivo distribution of [11C]-(+)-PHNO in the human brain, at baseline and 
after administration of various ascending doses of the selective D3 receptor antagonist 
GSK598809 (13)(in vitro Ki of 6.2 and 740 nM against [3H]-PHNO in filtration binding 
experiments on membranes obtained from Chinese hamster ovary (CHO) cells expressing human 
D3 and D2 receptors, respectively). Fifty two [11C]-(+)-PHNO scans were obtained in nineteen 
subjects, at baseline and after various doses of GSK598809.  Comparison of [11C]-(+)-PHNO 
binding at baseline and following D3 receptor blockade enabled dissection of the D2HIGH and D3 
receptor components of the [11C]-(+)-PHNO regional specific binding and quantification of 
regional D3 receptor binding potential in the living human brain. 
 
MATERIAL AND METHODS 
General design 
The study was approved by the Centre for Addiction and Mental Health (CAMH) 
Research Ethics Board and performed at the CAMH PET Centre, Toronto.  The study was 
sponsored by GlaxoSmithKline and the protocol was posted on clinicaltrial.gov (identifier 
NCT00468806) prior to study initiation.  Nineteen healthy volunteers were included in the study.  
Each subject received a baseline [11C]-(+)-PHNO scan and one to three [11C]-(+)-PHNO scans 
following administration of one to three oral doses  of GSK598809 (range from 5 to 175 mg).  
The post-challenge PET scans were scheduled to begin around two to three hours after 
administration in order to estimate occupancy shortly after the anticipated plasma peak.  Blood 
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samples were taken for analysis of GSK598809 pharmacokinetics. 
Subjects 
Inclusion criteria were: male non-smokers aged between 22 and 55 years old, with body 
mass index (BMI) between 19.0 – 29.0 kg/m2 and the absence of past or present neurological, 
medical, or psychiatric illnesses and concomitant medications.  Clinical status was assessed by 
history, review of systems, physical examination, routine blood tests, urine toxicology and EKG.  
Subjects provided written informed consent. 
Radiochemistry 
Radiosynthesis of [
11
C]-(+)-PHNO was performed as previously described (10).  Briefly, 
[
11
C]propionylchloride was reacted with 9-hydroxynaphthoxazine to generate a [
11
C]amide, 
which was subsequently reduced by lithium aluminium hydride.  Purification by HPLC and 
formulation gave radiochemically pure [
11
C]-(+)-PHNO as a sterile, pyrogen-free solution 
suitable for human studies. 
PET protocol 
Dynamic PET scans were acquired using a Siemens Biograph 16 HI-REZ PET-CT 
(Siemens Healthcare) in 3D mode.  A CT scan was acquired for attenuation correction of PET 
data prior to administration of the radiotracer.  The radiotracer was then administered as an 
intravenous bolus over 30 seconds, and dynamic PET data were acquired for 90 minutes.  The 
PET data were binned into 26 frames (durations: 8 x 15s, 3 x 60s, 5 x 2min, 5 x 5min, 5 x 10min) 
and reconstructed using Fourier rebinning and 2D filtered back projection with a ramp filter at 
Nyquist cut-off frequency.  Image data were smoothed with a Gaussian filter (5 mm FWHM). 
Arterial sampling for measurement of [11C]-(+)-PHNO input function was not performed.  A T1-
weighted image (FSPGR sequence) was also acquired for each subject using a GE Signa Excite 
HD 1.5T scanner system (GE Healthcare, U.S.A.).  
Image analysis 
Scans were analyzed at the Clinical Imaging Centre, GlaxoSmithKline, London.  
Dynamic PET images were registered to the subject’s MR image, and corrected for motion using 
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a frame-to-frame registration process with a mutual information cost function.  
Six regions of interests (ROI) were analyzed: ventral striatum (VST), dorsal caudate 
(DCA), dorsal putamen (DPU), globus pallidus (GP), thalamus (THA) and substantia nigra (SN).  
VST, DCA, DPU, GP and THA were defined manually on each subject’s MR image (14). SN 
was defined manually on each subject’s baseline PET integral image. The cerebellum (CER) was 
defined via nonlinear registration (using SPM5b; Wellcome Trust Centre for Neuroimaging, 
http://www.fil.ion.ucl.ac.uk/spm) of a template MR image and corresponding brain atlas.  Each 
ROI was then applied to the dynamic PET data to derive regional time-activity curves. 
[11C]-(+)-PHNO binding potential 
The binding potential relative to the nondisplaceable compartment ( NDBP ) is equal to the 
product of receptor density (Bmax), affinity of ligand for the target (1/KD) and the free fraction in 
the brain ( NDf ):  
BPND
fNDBmax
KD
.      (1) 
D2 receptors are configured in interconvertible states of high (D2HIGH) and low (D2LOW) 
affinity for agonists (15-17).  At the doses used in this study, the agonist [11C]-(+)-PHNO is 
expected to bind only to D2HIGH receptors.  In contrast, D3 receptors appear to be essentially 
configured in a single high affinity state for agonists (see references and discussion in (12)). 
Thus [11C]-(+)-PHNO NDBP  can be decomposed: 
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where 3DNDBP  and  
HIGHD
NDBP
2
are the NDBP for D3 and D2HIGH receptor sites, respectively. 
Quantitative analysis was performed using the simplified reference tissue model (SRTM, 
(18)) , with cerebellum as reference region, to derive regional estimates of NDBP .  Model fits and 
parameter estimates were obtained via the basis function implementation (19).  The occupancy of 
[11C]-(+)-PHNO induced by GSK598809 was quantified by relating NDBP  measured in the 
presence of GSK598809 (BPND GSK 598809) to baseline NDBP  (BPND Baseline ): 
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Occupancy
BPND Baseline BPNDGSK 598809
BPND Baseline
.     (3) 
Fraction of [11C]-(+)-PHNO NDBP corresponding to binding to D3 receptor (
3D
PHNOf ) 
The fraction of baseline [11C]-(+)-PHNO NDBP  corresponding to binding to D3 receptors 
( 3DPHNOf ) is: 
HIGHD
ND
D
ND
D
NDD
PHNO
BPBP
BP
f
23
3
3 ,      (4) 
where 3D
NDBP  and 
HIGHD
NDBP
2  are the baseline [11C]-(+)-PHNO binding potentials at the D3 
and D2HIGH sites respectively.  Occupancy by GSK598809 can be described by: 
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598809
598809
3
DGSK
P
GSK
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PHNO
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C
fOccupancy ,                        (5a) 
where 598809GSKPC  is the GSK598809 total plasma concentrations at the beginning of the 
scan, and 350
DEC  is the total plasma concentration of GSK598809 associated with 50% occupancy 
of brain D3 receptors.  In terms of NDBP , this relationship is: 
BPND
Measured BPND
Baseline fPHNO
D3
1
CP
GSK 598809
EC50
D3
1 fPHNO
D3 ,      (5b) 
where 
Baseline
NDBP  is baseline NDBP  and BPND
Measured
 is the NDBP measured in any given scan.   
Regional 
3D
PHNOf were estimated via model fits to all data from all ROIs simultaneously 
using Equation 5b.  The parameter 
3
50
DEC  was shared between regions, while each region had its 
own 
3D
PHNOf .  This analysis assumes that the affinity of GSK598809 for D3 receptors is invariant 
across regions and across subjects.  The estimation of regional 
3D
PHNOf  permitted the calculation of 
3D
NDBP  and 
HIGHD
NDBP
2
 values using Equation 4. 
This analysis also assumes that, at doses used in this study, GSK598809 binding to D2 
receptors was negligible.  To check this assumption, data were also analyzed using a two site 
model which accounted for possible occupancy of D2 receptors by GSK598809: 
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BPND
Measured BPND
Baseline fPHNO
D3
1
CP
GSK 598809
EC50
D3
1 fPHNO
D3
1
CP
GSK 598809
EC50
D2
,   (6b) 
where 250
DEC  is the plasma concentration of GSK598809 associated with 50% occupancy 
D2 receptors. 
 
RESULTS 
Summary scan data 
A total of 52 [11C]-(+)-PHNO scans were obtained in 19 subjects (19 baseline scans and 
33 scans following administration of GSK598809).  Doses used were 5 mg (3 scans), 25 mg (4 
scans), 50 mg (3 scans), 75 mg (14 scans), 130 mg (2 scans) and 175 mg (7 scans).  Subject ages 
were 36.2 ± 9.6 years (mean ± SD) and BMI was 25.1 ± 2.4 kg/m
2
.  
 
Eight subjects received two 
scans (one baseline and one after GSK598809 administration), eight subjects received three 
scans (baseline plus two scans after GSK598809 administrations) and three subjects received 
four scans (one baseline plus three scans after GSK598809 administrations).  [11C]-(+)-PHNO 
injected doses were 298 ± 50.3 MBq.  [11C]-(+)-PHNO injected masses were 2.36 ± 0.13 
micrograms.  For the post-GSK598809 scans, the interval between GSK598809 administration 
and [11C]-(+)-PHNO injections was 2.8 ± 1.5 hours.  For each subject, administrations of 
GSK598809 were separated by at least one week. 
Baseline scans 
Figure 1 shows a representative PET image (imaged summed over 10-90 min.), with 
coregistered MRI, showing the regional distribution of [11C]-(+)-PHNO uptake in the human 
brain.  High accumulation is observed in the striatal regions, GP and SN, and low levels in THA, 
CER and cortical regions.  [11C]-(+)-PHNO time activity curves and SRTM model fits under 
baseline conditions in one representative subject are presented in Figure 2a.  CER, THA and the 
striatal regions (VST, DCA and DPU) peaked early and displayed rapid wash-out.  In GP and 
SN, the washout was more protracted.  The SRTM was found to describe the tissue data well.  
Figure 3 summarises the calculated baseline [11C]-(+)-PHNO NDBP  in the 19 subjects. 
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Scans following GSK598809 administration 
Figure 4 shows representative [11C]-(+)-PHNO scans (imaged summed over 10-90 min.) 
at baseline (top) and after administration of 175 mg GSK598809 (bottom).  Slices were selected 
to illustrate the marked change in SN, moderate change in GP and VS, and marginal change in 
dorsal striatal regions following D3 receptor blockade.  Figure 2b shows [11C]-(+)-PHNO time 
activity curves and SRTM model fits after administration of 175 mg GSK598809 in the same 
subject as depicted in Figure 2a.  GSK598809 (175 mg) administration reduced [11C]-(+)-PHNO 
uptake in SN to levels comparable to the cerebellum.  The uptake was also significantly reduced 
in the GP.  Activities in dorsal striatal regions were unaffected. 
Derivation of 
3D
PHNOf  
The model described in Equation 5b was fitted to all subjects and all regions 
simultaneously.  Data and model fits are shown in Figure 5.  The two site model (Equation 6b) 
was also fitted to the data.  No significant improvement in model fit was produced and 
consideration of the Akaike Information Criterion (1-site: -810, 2-site: -809) indicated that the 
single site model was most appropriate.  Furthermore, estimation of 3DPHNOf  by Equation 5b and 
Equation 6b yielded nearly identical results.  Thus, only results of the one site model are 
presented here. 
Examination of the effects of GSK598809 on [11C]-(+)-PHNO NDBP  revealed marked 
differences between regions.  High GSK598809 plasma concentrations were associated with 
almost complete blockade of [11C]-(+)-PHNO specific binding in SN, and little detectable 
changes in the dorsal regions of the striatum.  Model fit results with confidence intervals are 
given in Table 1.  The lack of effect of GSK598809 in DCA and DPU resulted in 
3D
PHNOf  close to 
zero.  In contrast, 
3D
PHNOf  in SN was close to 100%.  VST, GP and THA produced intermediate 
values, with 
3D
PHNOf   of 0.26, 0.67 and 0.46, respectively.  Regional 
3D
PHNOf  estimates permitted the 
calculation of 3DNDBP  and 
HIGHD
NDBP
2
 in each region (Table 1 and Figure 6).  The highest 
concentration of D3 receptors were found in GP (
3D
NDBP  of 1.90), followed by SN (
3D
NDBP  of 
1.39), with lower levels in VST ( 3DNDBP  of 0.77) and THA (
3D
NDBP  of 0.18). 
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DISCUSSION 
Technical limitations 
Technical limitations of this study should be acknowledged.  No arterial input function 
was measured, and the SRTM was used to derive NDBP .  The SRTM is known to underestimate 
NDBP  in regions of high binding when the reference region does not follow a one compartment 
model in response to the true input function (20).  Full quantitative analysis of [11C]-(+)-PHNO 
uptake using arterial input function suggested that this could be the case for this tracer (21).  This 
effect could lead to a small underestimation of occupancy in high density regions, but would not 
change the main conclusions of this study.   
A second limitation resulting from the lack of input function measurement is the absence 
of quantification of the effects of GSK598809 on cerebellum distribution volume.  Like previous 
investigators, we considered the cerebellum as an appropriate region of reference, i.e. devoid of 
significant amounts of D3 receptors (11, 21-24).  However, on examination of cerebellar 
standard uptake values (SUVs, i.e. regional activity normalized by injected dose and body 
weight), a small dose dependent decrease in cerebellum SUVs was observed.  At the highest 
achieved D3 receptor blockade (175 mg dose), cerebellum SUVs decreased by about 30% in the 
late phase of the scans.  Such an effect could be due to changes in input function, to the presence 
of D3 receptors in cerebellum or to some combination of both factors.  This observation contrasts 
with the reported lack of effect of haloperidol on [11C]-(+)-PHNO cerebellum SUVs in humans 
(11).  There the small number of subjects examined (three) may have produced inadequate 
sensitivity to detect an effect.  Our observations were consistent with the decrease in [11C]-(+)-
PHNO cerebellum distribution volumes reported in baboons following administration of high 
doses of SB-277011 (12).  This effect could lead to a slight underestimation of regional 
3D
PHNOf , 
but would not affect the main conclusions of this study.  The possibility of signal contamination 
from adjacent regions (such as the vermis) was checked via definition of subdivisions of the 
cerebellar ROI.  Consistent changes in SUV values in cortical regions were also found, 
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suggesting that the effect cannot be attributed to inappropriate definition of the reference region.  
Studies with input function measurement, D3 receptor blockade and full quantitative analysis in 
humans are warranted to examine these issues. 
A further potential technical limitation relates to the definitions of the target-rich ROIs 
used.  Some of the regions considered are small and thus potentially sensitive to subject motion 
and image registrations.  Striatal regions such as DPU and GP lie close to each other and so there 
is some potential for spillover of signal between regions.  The GP is also possibly heterogenous 
in distribution of D2 and D3 receptors (25), and has somewhat indistinct boundaries on T1 MRI 
images.  This could increase variability in outcome parameters. 
Comparison with other data sets 
The fact that the differences between the in vivo regional distributions of [11C]-(+)-
PHNO and [11C]raclopride are primarily due to the preferential affinity of [11C]-(+)-PHNO for 
D3 receptors was first demonstrated in baboons, using the D3 partial agonist BP897 (3 baboons, 
six scans, single dose of 0.25 mg/kg, i.v., Table 2) (8).  The larger reduction in [11C]-(+)-PHNO 
NDBP  compared to [11C]raclopride NDBP  induced by BP897 showed that [11C]-(+)-PHNO was 
more selective than [11C]raclopride for D3 receptors.  These results were confirmed in baboons 
using the highly selective D3 receptor antagonist  SB-277011, and a dose-response curve method 
similar to that used here (3 baboons, 18 scans, 0.5, 2 and 5 mg/kg i.v., Table 2) (12).  A baboon 
study was also carried out with GSK598809 (3 baboons, 16 PET scans, dose range 0.1 to 1 
mg/kg i.v., unpublished data, Table 2).  Regional 
3D
PHNOf  values measured with GSK598809 in 
baboons were similar to those derived with SB-277011.  The results reported in this study are 
consistent with the baboon data, in the general magnitude and rank order of regional 
3D
PHNOf  (SN> 
GP> THA> VST> DCA> DPU).  The 
3D
PHNOf  obtained here for thalamus (46%) is somewhat 
lower than those reported in baboon studies (60% - 97%). However, as a result of the low [11C]-
(+)-PHNO binding potential in thalamus and consequently noisy data, our confidence interval for 
thalamus spans the full range from zero to one. Thus this difference should not be considered 
significant. 
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The results of this study differ with the results of a [11C]-(+)-PHNO occupancy study in 
humans with ABT-925, an antagonist with 50-100 fold selectivity for the D3 over the D2 in vitro 
(23).  ABT-925 reduced [11C]-(+)-PHNO NDBP  by a relatively large and comparable amount in 
both dorsal and ventral regions of the striatum (Table 2).  Here, the 175 mg dose of GSK598809 
had very little effect in dorsal striatum, while inducing nearly 100% displacement in the SN.  
These discrepant findings may be accounted for by a lower D3/D2 selectivity of ABT-925 
compared to GSK598809 in vivo.  A two site fit of the in vivo ABT-925 data indicated only a 2-
4 fold selectivity for D3 over D2 (23).  This suggestion is supported by results of in vitro 
35
S-
GTPγS functional inhibition studies against quinelorane on membranes obtained from CHO cells 
expressing human D3 and D2 receptors (according to the method described in (13), where ABT-
925 exhibited fpKi values of 8.19 and 7.01 at D3 and D2 receptors, respectively (about 15 fold 
selectivity)), while GSK598809 exhibited fpKi values of 8.9 and 6.2, at D3 and D2 receptors, 
respectively (about 500 fold selectivity). 
D3 and D2 receptor distribution 
The lack of detectable D3 receptor signal in the dorsal striatum is consistent with the low 
levels of expression of these receptors documented in human postmortem studies.  Seeman et al. 
(26) failed to detect any D3 receptor binding in dorsal regions of the human striatum, whilst other 
investigators detected low levels of D3 receptors in dorsal striatum (25, 27).  This study does not, 
however, rule out the existence of low levels of D3 receptors in the striatum, which could have 
been obscured by the technical limitations discussed above. 
Significant concentrations of D3 receptors were detected in VST, GP and SN, regions 
where high expression of D3 receptors have been documented postmortem (25, 27). The fraction 
of observed PHNO signal in GP attributed here to D3 (67%) is somewhat higher than the value of 
35% determined in the autoradiographic studies of Seeman et al. (26), though consistent with 
other in vivo experiments (see  Table 2). This disparity could be due to differences between the 
in vitro and in vivo settings.  It has been suggested that [11C]-(+)-PHNO binding to D3 receptors 
in the GP can increase in response to long term administration of D2 antagonists (28), however a 
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similar effect here is considered unlikely since GSK598809 was administered acutely. The 
presence of D3 receptors in SN is compatible with their proposed function as autoreceptors, 
although the majority of D3 receptors in the SN may not be located on DA cells (29-30).  
Interestingly, in Parkinson’s patients, [11C]-(+)-PHNO binding in the SN is not decreased, 
supporting the notion that the majority of D3 receptors in that area are not located on DA cells 
(22).  
The lack of detection of D2HIGH receptors in SN with [11C]-(+)-PHNO might seem 
surprising given the well documented presence of D2 receptors in SN.  However, it should be 
remembered that the measured PET signal ( NDBP ) is proportional to DKBmax .  Thus if the 
ligand has different affinities for the two binding sites then the fraction 3DPHNOf  of NDBP  
corresponding to D3 binding can be very different from the D3 fraction of receptor concentration 
( fB max
D3 ).  The in vivo affinities of [11C]-(+)-PHNO for D3 and D2HIGH receptors were recently 
measured in rhesus monkeys using PET and a two site model (31).  The potency of (+)-PHNO to 
block [11C]-(+)-PHNO was about 20-fold higher in SN compared to dorsal striatum, indicating a 
20-fold in vivo selectivity ( 32 DD
HIGHD
D KK ) of [11C]-(+)-PHNO for D3 compared to D2HIGH.  
Given this level of selectivity, it is entirely plausible that a region could have a substantial 
fraction HIGHDBf
2
max , yet a small contribution of D2HIGH receptors to [11C]-(+)-PHNO NDBP .  If we 
suppose that the same 20-fold in vivo selectivity exists in human, then Equation 4 can be 
rewritten as  
             (7) 
 
Baboon PET experiments with [18F]fallypride (32) and human in vitro experiments (25, 
27) suggest that around 40% of the D2-like receptors in SN are D3.  Applying Equation 7, a 40% 
D3 receptor concentration fraction could be expected to translate into a 
3D
PHNOf value of around 
95%, consistent with the results presented here.  Further PET experiments in humans using 
GSK598809 and a radioligand such as [18F]fallypride could be employed to obtain a more 
precise estimate of the relative densities of D2 and D3 receptors in the SN. 
.
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Implications for imaging studies 
The results of this study have implications for future imaging studies with [11C]-(+)-
PHNO.  First, at a time when several selective D3 receptor antagonists and “optimized” D3/D2 
receptor antagonists are under development (1-3), [11C]-(+)-PHNO scans in healthy volunteers 
provide a simple method to simultaneously quantify the in vivo occupancy at both D3 and D2 
receptors by examining the decrease in [11C]-(+)-PHNO NDBP  in SN and dorsal striatum, 
respectively. 
Second, this study informs the emerging literature reporting the distribution of [11C]-(+)-
PHNO NDBP  in pathological conditions.  For example, Graff-Guerrero et al. (24) reported 
unchanged [11C]-(+)-PHNO NDBP  in drug-free patients with schizophrenia, a result that might 
seem at variance with the postmortem finding of significant upregulation of D3 receptors in VST 
in schizophrenia (33).  However, since only about 26% of VST [11C]-(+)-PHNO NDBP  
corresponds to binding to D3 receptors, such an upregulation, if present, might have been 
obscured by the mixed nature of the VST [11C]-(+)-PHNO signal.  Boileau et al. (22) studied 
[11C]-(+)-PHNO and [11C]raclopride distributions in PD patients.  Regions were classified as D3 
“rich” (VST and GP) or D2 receptor “rich” (DCA and DPU).  In PD subjects, [11C]raclopride 
and [11C]-(+)-PHNO NDBP ’s were increased in DPU, [11C]-(+)-PHNO but not [11C]raclopride  
NDBP ’s were decreased in GP,  and both ligands were unaffected in the VST.  The authors 
interpreted the results as demonstrating an upregulation of D2 receptors in DPU and a 
downregulation of D3 receptors in GP, an interpretation that is in line with the results of the 
present study.  It is unclear if the lack of findings in the VST is due to this region being relatively 
unaffected in PD, or to the fact that D3 receptors contribute only a small fraction of [11C]-(+)-
PHNO specific binding in VST.  Future studies with [11C]-(+)-PHNO aiming at characterizing 
D2HIGH and D3 distributions with [11C]-(+)-PHNO in mixed regions (VST, GP, THA) will 
benefit from the combination of a baseline scan with a scan obtained following administration of 
a selective D3 receptor antagonist.  This would be especially important in the study of addictive 
conditions, where D2 and D3 receptors have been showed to be decreased and increased, 
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respectively (reviewed in (4, 34)). 
 
CONCLUSIONS 
In conclusion, this study elucidated the pharmacological nature of the [11C]-(+)-PHNO 
signal in healthy subjects, and provided quantification of D3 receptor availability in the living 
human brain.  The [11C]-(+)-PHNO signal was found to be relatively selective for D2HIGH in 
DCA and DPU, and for D3 in SN, while it was mixed in VST, GP and THA.  The highest 
concentration of D3 receptors were found in GP (
3D
NDBP  of 1.90), followed by SN (
3D
NDBP  of 
1.39), with lower levels in VST ( 3D
NDBP  of 0.77) and THA (
3D
NDBP  of 0.18).  Given the relatively 
selective nature of the [11C]-(+)-PHNO signal in DCA, DPU and SN, [11C]-(+)-PHNO can be 
used to measure drug-induced occupancy at both D2HIGH and D3 receptors in healthy volunteers.  
In the absence of truly selective D2 or D3 PET radioligands, the combination of [11C]-(+)-PHNO 
and a selective D3 receptor antagonist provides a method for dissecting D3 and D2HIGH receptor 
availability in mixed regions such as VST and GP.  The ability to measure D3 receptors in health 
and disease, as well as the level of engagement of this target by therapeutic agents, will be very 
valuable to unravel the role of D3 receptors in the pathophysiology and treatment of 
neuropsychiatric conditions. 
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Table 1.  Estimated binding of [11C]-(+)-PHNO to D3 and D2HIGH receptors in the human brain 
 
Parameter 
(unitless) 
Regions 
 SN GP VST THA DCA DPU 
3D
PHNOf  
1.00 
(0.79-1.00) 
0.67 
(0.55-0.80) 
0.26 
(0.18-0.35) 
0.46 
(0.00-1.00) 
0.01 
(0-0.14) 
0.00 
(0.00-0.11) 
NDBP  
1.39 
(1.28-1.49) 
2.83 
(2.72-2.93) 
2.94 
(2.83-3.04) 
0.39 
(0.28-0.49) 
1.85 
(1.75-1.95) 
2.37 
(2.26-2.47) 
3D
NDBP  1.39 1.90 0.77 0.18 0.02 0.00 
HIGHD
NDBP
2
 0.00 0.92 2.16 0.21 1.83 2.37 
 
  
Parameters estimated using the model described in Equation 5b: fraction of baseline [11C]-(+)-PHNO 
NDBP corresponding to binding to 
D3 receptors ( 3DPHNOf ), total baseline [
11C]-(+)-PHNO 
NDBP  and baseline [
11C]-(+)-PHNO 
NDBP  to D3 (
3D
NDBP ) and D2HIGH 
( HIGHD
NDBP
2 ) receptor sites in various regions of the human brain (substantia nigra, SN; globus pallidus, GP; ventral striatum, VST; 
thalamus, THA; dorsal caudate, DCA; dorsal putamen, DPU). The values for 3D
NDBP  and  
HIGHD
NDBP
2  were calculated directly from the 
model parameters 3D
PHNOf  and NDBP  which were fitted to the data acquired. Values in parentheses represent 95% confidence intervals. 
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Table 2.  Comparison of [11C]-(+)-PHNO in vivo pharmacological studies. 
 
Species Agent Source SN GP VST THA DCA DPU 
Baboon BP897 (8) 90% 57% 30% 60% 13% 13% 
Baboon SB27011 (12) 100% 72% 49% 82% 23% 8% 
Baboon GSK598809 Unpublished data 90% 89% 58% 97% 22% 4% 
Human GSK598809 This study 100% 67% 26% 46% 1% 0% 
Human ABT925 (23) 100% 90% 62% - 55% 53% 
 
  
Fraction of [11C]-(+)-PHNO 
NDBP displaceable by putative D3 receptor selective agents, in baboons and humans, in various brain regions 
(substantia nigra, SN; globus pallidus, GP; ventral striatum, VST; thalamus, THA; dorsal caudate, DCA; dorsal putamen, DPU) in baboons and 
human studies. * Value for dorsal striatum. -, not reported.  See text for doses. 
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FIGURE LEGENDS 
 
Figure 1.  Baseline [11C]-(+)-PHNO integral images (summed over 10-90 min.) (top row) and 
associated MR image (bottom row) in one representative subject. Sections on the left were selected to 
show the substantia nigra (SN) region.  Sections on the right show dorsal caudate (DCA), dorsal 
putamen (DPU), ventral striatum, (VST) globus pallidus (GP) and thalamus (THA). 
Figure 2.  [11C]-(+)-PHNO time activity curves and SRTM model fits in one subject at  
baseline (top) and after oral administration of 175 mg of GSK598809 (bottom) showing cerebellum, 
CER; substantia nigra, SN; globus pallidus, GP; ventral striatum, VST; thalamus, THA; dorsal caudate, 
DCA; dorsal putamen, DPU.  At baseline, regions of highest uptake include the three striatal regions 
(VST, DCA, DPU), GP and SN, while THA activity is only marginally higher than CER.  CER, THA 
and the three striatal regions (VST, DCA,DPU) display early peaks followed by rapid wash-out.  In GP 
and SN, the wash-out rate is more protracted.  Following 175 mg GSK598809, SN uptake decreased to 
the CER levels, GP was reduced, and striatal regions were only mildly affected. 
Figure 3.  Mean ± SD of measured [11C]-(+)-PHNO NDBP  in six ROIs during baseline scans (n 
= 19). Legend: substantia nigra, SN; globus pallidus, GP; ventral striatum, VST; thalamus, THA; 
dorsal caudate, DCA; dorsal putamen, DPU. 
Figure 4.  [11C]-(+)-PHNO integral images (summed over 10-90 min.) at baseline (top row) and 
after administration of 175 mg GSK598809 (bottom row). Slices are selected to illustrate the marked 
change in SN, moderate change in GP and VST, and marginal change in dorsal striatal regions. 
Figure 5. Plots of [11C]-(+)-PHNO displacement against plasma concentration of GSK598809 
in six brain regions. Solid lines represent model fits (via Equation 5) to the measured data. Legend: 
substantia nigra, SN; globus pallidus, GP; ventral striatum, VST; thalamus, THA; dorsal caudate, 
DCA; dorsal putamen, DPU.  The asymptotes of the curves provided 
3D
PHNOf .  At high concentrations, 
GSK598809 almost completely blocked the specific binding of [11C]-(+)-PHNO in SN, with negligible 
effects on the DCA and DPU. 
Figure 6.  Measured baseline [11C]-(+)-PHNO NDBP  divided into portions corresponding to D3 
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receptors  ( 3D
NDBP , black area) and D2HIGH receptor (
HIGHD
NDBP
2 , grey area) by regions.  3D
NDBP  obtained 
by multiplying [11C]-(+)-PHNO BPND by 
3D
PHNOf , 
HIGHD
NDBP
2
 obtained as NDBP  minus 
3D
NDBP . Legend: 
substantia nigra, SN; globus pallidus, GP; ventral striatum, VST; thalamus, THA; dorsal caudate, 
DCA; dorsal putamen, DPU. 
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